Physician profile
Nancy S Weigel
NPI 1508834128
$5,752.34
in general payments reported to CMS, 2019-2025
37 companies · $955 in 2025
The $955 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $790 · 2021: $949 · 2022: $672 · 2023: $694 · 2024: $909 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $739.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $708.91 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Lilly USA, LLC | $505.78 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $479.94 | 2019-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $470.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.40 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $372.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $278.82 | 2020-2023 | |
| Glaxosmithkline, LLC. | $186.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.40 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.48 | 2020-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $126.44 | 2023-2025 | Gemtesa |
| Amgen INC. | $119.36 | 2019-2021 | |
| Mylan Specialty L.P. | $115.72 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $97.97 | 2022-2024 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $85.30 | 2024-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $82.25 | 2020-2022 | |
| Abbott Laboratories | $81.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $77.49 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.50 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $66.24 | 2019-2021 | |
| Amarin Pharma, INC. | $61.88 | 2020-2021 | |
| Seqirus USA INC | $57.18 | 2024-2025 | Flucelvax, Fluad |
| Radius Health, INC. | $57.01 | 2019-2021 | |
| Allergan, INC. | $31.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.31 | 2019 | |
| Antares Pharma, INC. | $27.72 | 2024 | Xyosted |
| Lundbeck LLC | $23.53 | 2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $20.30 | 2020 | |
| Phadia US INC. | $19.93 | 2023 | Immunocap |
| Xeris Pharmaceuticals, INC. | $17.83 | 2022 | |
| Eisai INC. | $15.92 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2020 | |
| Exact Sciences Corporation | $13.10 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2020 | |
| Alkermes, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Weigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.